Mavacamten Patent Expiration
Mavacamten is Used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. It was first introduced by Bristol Myers Squibb Co
Mavacamten Patents
Given below is the list of patents protecting Mavacamten, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Camzyos | USRE50050 | Pyrimidinedione compounds | Apr 28, 2036 | Bristol |
| Camzyos | US9181200 | Pyrimidinedione compounds | Jun 19, 2034 | Bristol |
| Camzyos | US9585883 | Pyrimidinedione compounds | Jun 19, 2034 | Bristol |
Mavacamten's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Mavacamten:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy | Bristol-Myers Squibb | NA |
TERMINATED
(Aug 1, 2026)
| PHASE3 |